Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SALUTENSIN-DEMI vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hydroflumethiazide is minimally metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Hydrochlorothiazide: 40-68% (primarily to albumin); Reserpine: approximately 40% (to albumin and α1-acid glycoprotein)
Approximately 70-80% bound to plasma proteins, primarily albumin.
Hydrochlorothiazide: 0.2-0.4 L/kg (distributes in extracellular fluid); Reserpine: 5-10 L/kg (extensive tissue distribution, high affinity for adrenergic neurons)
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: hydrochlorothiazide 65-75%; reserpine 30-50% (extensive first-pass metabolism)
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated in GFR <30 m L/min. For GFR 30-50 m L/min: use maximum 1 tablet daily; monitor electrolytes and renal function.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., every other day). Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not recommended for pediatric use due to lack of safety and efficacy data; alternative agents preferred.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start with 0.5 tablet (7.5 mg hydrochlorothiazide + 0.0375 mg clonidine) once daily; monitor for orthostatic hypotension, electrolyte imbalance, and renal function; avoid in patients with high frailty.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
Electrolyte imbalances (hypokalemia, hyponatremia),Orthostatic hypotension,Depression (reserpine component),Potential for increased risk of non-melanoma skin cancer with thiazide diuretics,May exacerbate systemic lupus erythematosus
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Known hypersensitivity to sulfonamide-derived drugs (hydroflumethiazide),Anuria,History of mental depression (reserpine-containing products),Active peptic ulcer or ulcerative colitis,Concomitant use with MAO inhibitors
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, leafy greens) as thiazide can cause potassium loss; however, reserpine may increase potassium retention. Maintain balanced diet. Limit sodium intake to control blood pressure. Avoid grapefruit juice as it may increase reserpine absorption.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydramnios, skull ossification delay. Avoid use unless benefit outweighs risk.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excreted in breast milk; M/P ratio not reported. Risk of infant hypotension and renal impairment. Use caution, monitor infant blood pressure and renal function.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Dose may need reduction due to increased volume of distribution and altered drug clearance. Adjust based on clinical response and maternal blood pressure. Monitor for hypotension and electrolyte imbalance.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Salutensin-demi contains reserpine (rauwolfia alkaloid) and a thiazide diuretic. Monitor for depression, nasal stuffiness, and hypotension. Avoid concurrent MAOIs. Use with caution in patients with a history of peptic ulcer disease due to increased gastric acid secretion from reserpine.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed, usually once daily in the morning.,Avoid sudden discontinuation; taper dose to prevent rebound hypertension.,Report signs of depression, nightmares, or severe drowsiness.,May cause dizziness upon standing; rise slowly from sitting or lying.,Notify your doctor if you develop abdominal pain, black stools, or unusual bleeding.,Avoid alcohol, which can increase drowsiness and hypotension.,Take with food or milk to lessen stomach upset.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SALUTENSIN-DEMI vs ALDOCLOR-150, answered by our medical review team.
SALUTENSIN-DEMI is a Antihypertensive Combination that works by Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SALUTENSIN-DEMI and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SALUTENSIN-DEMI is: 1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SALUTENSIN-DEMI and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SALUTENSIN-DEMI is classified as Category C. First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydr. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.